Synonyms: CLM-001 | IPN-60120 | IPN60120 | R-667 | R667 | RG-667 | Ro-3300074 | Sohonos®
palovarotene is an approved drug (Canada (2022), FDA (2023))
Compound class:
Synthetic organic
Comment: Palovarotene is an orally bioavailable, retinoic acid receptor gamma (RAR-γ) agonist. This compound was originally investegated for its potential to repair alveolar damage in emphysema and COPD [1,8], but it failed to demonstrate significant clinical efficacy. Ipsen acquired palovarotene when it purchased Clementia Pharmaceuticals in 2019, and they repurposed palovarotene for potential to reduce heterotopic ossification in patients with fibrodysplasia ossificans progressiva (FOP) [6,9].
|
|
Classification | |
Compound class | Synthetic organic |
Approved drug? | Yes (Canada (2022), FDA (2023)) |
IUPAC Name |
4-[(E)-2-[5,5,8,8-tetramethyl-3-(pyrazol-1-ylmethyl)-6,7-dihydronaphthalen-2-yl]ethenyl]benzoic acid |
International Nonproprietary Names | |
INN number | INN |
9025 | palovarotene |
Synonyms |
CLM-001 | IPN-60120 | IPN60120 | R-667 | R667 | RG-667 | Ro-3300074 | Sohonos® |
Database Links | |
ChEMBL Ligand | CHEMBL2105648 |
DrugBank Ligand | DB12320 |
GtoPdb PubChem SID | 252166488 |
PubChem CID | 10295295 |
Search Google for chemical match using the InChIKey | YTFHCXIPDIHOIA-DHZHZOJOSA-N |
Search Google for chemicals with the same backbone | YTFHCXIPDIHOIA |
Search PubMed clinical trials | palovarotene |
Search PubMed titles | palovarotene |
Search PubMed titles/abstracts | palovarotene |
UniChem Compound Search for chemical match using the InChIKey | YTFHCXIPDIHOIA-DHZHZOJOSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | YTFHCXIPDIHOIA-DHZHZOJOSA-N |